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The Thrombolysis in
ase I1 focused on the 
of patients with acute myocardial infarction after tbrom- 
bolytic treatment with intravenous recombinant tissue-type 
plasminogen activator (r&PA) and was designed to deter- 
mine which of three alternative post-thrombolytic treatment 
strategies was preferable: 1)an immediate invasive strategy, 
in which the patient was taken directly to the catheterization 
laboratory for coronary arteriography and, if feasible, per- 
cutaneous transluminal angioplasty during infusion of &PA; 
2) a delayed invasive strategy, in which routine coronary 
angiography was performed between 18 and 48 h after &PA 
therapy; and 3) a conservative strategy, in which coronary 
arteriography and, if indicated, angioplasty, were carried out 
only if the patient developed spontaneous or exercise- 
provoked myocardial ischemia. For patients assigned toone 
of the two invasive strategy groups, ifcoronary angiog~phy 
disclosed significant (MI%) stenosis of the infarct-related 
artery, revascularization was to be attempted (using coro- 
nary angioplasty if technically possible) according to proto- 
col-specified anatomic and clinical criteria (1,2). Patient 
entry began on April II, 1986 and ended on June 30, 1988 
with enrollment of 3,534 patients. Trial results were pre- 
sented for the first time in November 1988 and described in
two publications (I ,2). The constraint ofavailable space for 
these first two reports did not permit full discussion ofthe 
concepts underlying the design of the trial and the interpre- 
tation of the results. Additional nalyses of the results have 
now been performed (3-7). The purpose of this editorial isto 
provide additional information a d perspectives onTI 
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was attempted. The remaiu~ng 39.5% (n = 593) of patients 
who underwent catbeteriza~iou in of the ocol 
did not have angioplasty performe bad < ste- 
nosis of the infarct-related artery, 12.2% had total occlusion 
with no ongoing manifestations of ischemia 13.1% d 
complex coronary anatomy that was conside obebr r 
managed by bypass surgery or medical therapy. Th e 
exclusions from attempted coronary angioplasty were 
deemed appropriate in light of current 
(24.3%) of these 593 patients required coronary artery by- 
ry within 21 days. 
ive versus e~u~~ative s&a y. Patients assigned to
the delayed invasive strategy described were compared with 
1,658 patients assigned to a conservative strategy, in which 
cardiac athete~zation was reserved for the 587 patients 
(35.4%) who had either spontaneous 
myocardial ischemia within 21 days of 
13.5% of patients inthis arm of the Trial underwent coronary 
angioplasty, 7.6% underwent bypass urgery and 1.1% un- 
*The numbers presented in this editorial reflect the information available 
(0 the TIM1 Data Coordinating Center on August 8, 1989 and therefore 
represent an update of the data previously published (1,2). 
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coronary a~~~op~asty ia the invasive strategy group when 
there was no evidence of criti 
anatomy was unsuitable is a cl1 
s with every clinical trial, the results are 
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most applicable topatients similar to those entered into the 
trial. Of great interest are ongoing trials involving patients 
>76 years old, patients who present with ischemic chest pain 
and ST segment depression and patient 
after the onset of symptoms. However, 
apply in full to the substantial number 
ty criteria used to select he actual partici- 
II Trial. Thus far, analyses ofmany patient 
subgroups have failed to identify any in whom the invasive 
strategy was superior to the conservative one. 
The results of any trial 
of the operators. In 1986, when the 
criteria for operator certification were ed on then current 
recommendations f r the performance of angiopla 
patients) a primary success rate 
tion rate c7%, an emergency 
mortality rate <2%. Operators int 
included a more demanding immediate catheterization and 
oplasty arm) were required to have performed more than 
angioplasty procedures, at least 29 of which were in 
patients with total occlusion. These were minimal requ 
ments; many operators had much greater ex~e~e~ce. 
operators met hese requirements a  the 
and developed substantially greater ex 
gery. However, the net benefit of 
anatomically more complex situations i unclear 
larly given the unfavorable effects of a more 
application of angioplasty in the trial carried out by the 
kropean Cooperative Study Group (10). It is unlikely that 
requiring reater operator experience would have affected 
the outcome of the trial substantially b ~rn~rov~~g angio- 
plasty results. The high 
ment with a~gio~lasty, t 
gency surgery and lo 
related mortality inthe sive arm of the study are 
among the bes results of coronary an sty in a 
group of early tion patients. Finally, 
enced or expert angioplasty operators are not available to 
treat most patients with acute myocardial infarction. 
with intravenous 
e results of the “ 
amined only three well define 
whose total occlusio 
se 
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, aspirin may be of 
incremental v lue to the fibrinolytic actions of tbrombol 
gents in the treatment ofacute myocardial infarction. 
clinical trials have differed markedly in terms of the time, 
dose and route of aspirin administration. At its onset, T
II included an immediate oral dose (80 mg) of aspirin at 
time the 150 mg rt-PA and heparin infusions were initiated. 
With the recognition fa higher than expected incidence of
central nervous ystem bleeding events, the r&PA dose was 
reduced (150 to KM mg), and the initiation of aspirin therapy 
was delayed h (1). Thus, patients in t 
invasive arm I IIA (and a very small per 
delayed invasive arms) underwent coronar 
without prior aspirin therapy, a situation that m 
increase the incidence of postangioplasty ab 
mediate aspirin thera 
compari 
strategie 
would not be anticipated to have any 
main comparison f the delayed invasive strategy group with 
the conservative strategy group, because virtually all pa- 
tients received aspirin before delayed angioplasty. 
Given the many thrombolytic agents and the 
ways in which they CLEI be combined with 
revascularization, the treatment of acute myoc 
tion has been the subject of active study and lively debate, 
which are likely to continue for some time. Several studies, 
including TM IIA (2,3,10,22), hav 
diate catheterization and angioplasty 
and have a greater c 
invasive strategy, but 
suggested that an even more conservative strategy ofreserv- 
ing catheterization and coronary angioplasty after throm- 
bolytic therapy for patients with recurrent spontaneous OP
exercise-induced ischemia may be the most desirable ap- 
proach for the majority of patients similar to those ntered 
into these trials. 
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